Ligand Pharmaceuticals buying Xoma Royalty for $739 million
Summary
The all-cash deal adds more than 120 assets to Ligand's portfolio and is expected to close in the third quarter of 2026
Description
The all-cash deal adds more than 120 assets to Ligand's portfolio and is expected to close in the third quarter of 2026
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source